JP2016513737A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513737A5 JP2016513737A5 JP2016502870A JP2016502870A JP2016513737A5 JP 2016513737 A5 JP2016513737 A5 JP 2016513737A5 JP 2016502870 A JP2016502870 A JP 2016502870A JP 2016502870 A JP2016502870 A JP 2016502870A JP 2016513737 A5 JP2016513737 A5 JP 2016513737A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- cancer
- compound
- chemotherapeutic agent
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 63
- 239000002246 antineoplastic agent Substances 0.000 claims description 35
- 229940127089 cytotoxic agent Drugs 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 25
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 24
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims description 21
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 229910052717 sulfur Inorganic materials 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 15
- 125000004429 atom Chemical group 0.000 claims description 13
- 241000701806 Human papillomavirus Species 0.000 claims description 12
- 230000002159 abnormal effect Effects 0.000 claims description 12
- 230000004663 cell proliferation Effects 0.000 claims description 10
- 102000013698 Cyclin-Dependent Kinase 6 Human genes 0.000 claims description 9
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 201000000582 Retinoblastoma Diseases 0.000 claims description 8
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 230000010076 replication Effects 0.000 claims description 8
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 8
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 7
- 229960004562 carboplatin Drugs 0.000 claims description 7
- 238000002512 chemotherapy Methods 0.000 claims description 7
- 229960004316 cisplatin Drugs 0.000 claims description 7
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 229960005420 etoposide Drugs 0.000 claims description 7
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 239000012625 DNA intercalator Substances 0.000 claims description 4
- 230000006820 DNA synthesis Effects 0.000 claims description 4
- 230000004568 DNA-binding Effects 0.000 claims description 4
- 229940123573 Protein synthesis inhibitor Drugs 0.000 claims description 4
- 230000006819 RNA synthesis Effects 0.000 claims description 4
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 4
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims description 4
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 229940100198 alkylating agent Drugs 0.000 claims description 4
- 239000002168 alkylating agent Substances 0.000 claims description 4
- 230000022131 cell cycle Effects 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 239000000007 protein synthesis inhibitor Substances 0.000 claims description 4
- 150000003413 spiro compounds Chemical class 0.000 claims description 4
- 239000003277 telomerase inhibitor Substances 0.000 claims description 4
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 4
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 4
- 239000000225 tumor suppressor protein Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims 41
- 229940079593 drug Drugs 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 15
- 229960000303 topotecan Drugs 0.000 claims 6
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 6
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 206010005003 Bladder cancer Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 230000008034 disappearance Effects 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 45
- 125000000753 cycloalkyl group Chemical group 0.000 description 20
- 125000003118 aryl group Chemical group 0.000 description 14
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 12
- 125000001072 heteroaryl group Chemical group 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 125000003710 aryl alkyl group Chemical group 0.000 description 10
- 125000001188 haloalkyl group Chemical group 0.000 description 10
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- -1 heterocyclo Chemical group 0.000 description 7
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 210000001985 kidney epithelial cell Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 1
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- 0 CC(C)CC(CN1*)[n]2c3nc(NC4=CC=C(*)**4)ncc3cc2C1=O Chemical compound CC(C)CC(CN1*)[n]2c3nc(NC4=CC=C(*)**4)ncc3cc2C1=O 0.000 description 1
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 1
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- TWTKMJWAXOPXSX-UHFFFAOYSA-N O=C(c1c2)NCC3(CCCCC3)[n]1c1c2cnc(Nc(cc2)ncc2N2CCNCC2)n1 Chemical compound O=C(c1c2)NCC3(CCCCC3)[n]1c1c2cnc(Nc(cc2)ncc2N2CCNCC2)n1 TWTKMJWAXOPXSX-UHFFFAOYSA-N 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 229940116355 PI3 kinase inhibitor Drugs 0.000 description 1
- 239000012828 PI3K inhibitor Substances 0.000 description 1
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 1
- 229940078123 Ras inhibitor Drugs 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000001717 carbocyclic compounds Chemical class 0.000 description 1
- 230000001767 chemoprotection Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361798772P | 2013-03-15 | 2013-03-15 | |
| US61/798,772 | 2013-03-15 | ||
| US201361861374P | 2013-08-01 | 2013-08-01 | |
| US61/861,374 | 2013-08-01 | ||
| US201361911354P | 2013-12-03 | 2013-12-03 | |
| US61/911,354 | 2013-12-03 | ||
| US201461949786P | 2014-03-07 | 2014-03-07 | |
| US61/949,786 | 2014-03-07 | ||
| PCT/US2014/028685 WO2014144326A1 (en) | 2013-03-15 | 2014-03-14 | Transient protection of normal cells during chemotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018204234A Division JP6767456B2 (ja) | 2013-03-15 | 2018-10-30 | 化学療法の間の正常細胞の一時的な保護 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016513737A JP2016513737A (ja) | 2016-05-16 |
| JP2016513737A5 true JP2016513737A5 (enExample) | 2017-04-20 |
| JP6430483B2 JP6430483B2 (ja) | 2018-11-28 |
Family
ID=51527871
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503092A Active JP6337083B2 (ja) | 2013-03-15 | 2014-03-14 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
| JP2016502870A Active JP6430483B2 (ja) | 2013-03-15 | 2014-03-14 | 化学療法の間の正常細胞の一時的な保護 |
| JP2018089382A Active JP6517401B2 (ja) | 2013-03-15 | 2018-05-07 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
| JP2018204234A Active JP6767456B2 (ja) | 2013-03-15 | 2018-10-30 | 化学療法の間の正常細胞の一時的な保護 |
| JP2019077828A Active JP6738933B6 (ja) | 2013-03-15 | 2019-04-16 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
| JP2020123189A Active JP7250737B2 (ja) | 2013-03-15 | 2020-07-17 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
| JP2020155691A Active JP7213854B2 (ja) | 2013-03-15 | 2020-09-16 | 化学療法の間の正常細胞の一時的な保護 |
| JP2023005413A Ceased JP2023052449A (ja) | 2013-03-15 | 2023-01-17 | 化学療法の間の正常細胞の一時的な保護 |
| JP2023044746A Withdrawn JP2023078341A (ja) | 2013-03-15 | 2023-03-20 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503092A Active JP6337083B2 (ja) | 2013-03-15 | 2014-03-14 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
Family Applications After (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018089382A Active JP6517401B2 (ja) | 2013-03-15 | 2018-05-07 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
| JP2018204234A Active JP6767456B2 (ja) | 2013-03-15 | 2018-10-30 | 化学療法の間の正常細胞の一時的な保護 |
| JP2019077828A Active JP6738933B6 (ja) | 2013-03-15 | 2019-04-16 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
| JP2020123189A Active JP7250737B2 (ja) | 2013-03-15 | 2020-07-17 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
| JP2020155691A Active JP7213854B2 (ja) | 2013-03-15 | 2020-09-16 | 化学療法の間の正常細胞の一時的な保護 |
| JP2023005413A Ceased JP2023052449A (ja) | 2013-03-15 | 2023-01-17 | 化学療法の間の正常細胞の一時的な保護 |
| JP2023044746A Withdrawn JP2023078341A (ja) | 2013-03-15 | 2023-03-20 | Ｒｂポジティブ異常細胞増殖に対するｈｓｐｃ温存治療 |
Country Status (18)
| Country | Link |
|---|---|
| US (15) | US9527857B2 (enExample) |
| EP (4) | EP2968290B1 (enExample) |
| JP (9) | JP6337083B2 (enExample) |
| CN (4) | CN108283644B (enExample) |
| CA (2) | CA2906166C (enExample) |
| CY (1) | CY1122434T1 (enExample) |
| DK (1) | DK2968290T3 (enExample) |
| ES (2) | ES3032492T3 (enExample) |
| HR (1) | HRP20192168T1 (enExample) |
| HU (1) | HUE046653T2 (enExample) |
| LT (1) | LT2968290T (enExample) |
| ME (1) | ME03557B (enExample) |
| PL (1) | PL2968290T3 (enExample) |
| PT (1) | PT2968290T (enExample) |
| RS (1) | RS59790B1 (enExample) |
| SI (1) | SI2968290T1 (enExample) |
| SM (1) | SMT201900681T1 (enExample) |
| WO (2) | WO2014144847A2 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
| US8691830B2 (en) | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| EP3216792B1 (en) | 2012-03-29 | 2020-05-27 | G1 Therapeutics, Inc. | Lactam kinase inhibitors |
| CN104302620A (zh) | 2012-04-26 | 2015-01-21 | 弗朗西斯·泽维尔·塔瓦雷斯 | 内酰胺的合成 |
| CN105407723A (zh) | 2013-03-15 | 2016-03-16 | G1治疗公司 | 高效的抗赘生剂和抗增生剂 |
| WO2014144847A2 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| WO2015161285A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation |
| EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| US20160220569A1 (en) * | 2015-02-03 | 2016-08-04 | G1 Therapeutics, Inc. | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy |
| CA2989456C (en) * | 2015-06-17 | 2022-01-04 | Pfizer Inc. | Tricyclic compounds and their use as phosphodiesterase inhibitors |
| WO2017037575A1 (en) * | 2015-08-28 | 2017-03-09 | Novartis Ag | A pharmaceutical combination comprising the pi3k inhibitor alpelisib and the cdk4/6 inhibitor ribociclib, and the use thereof in the treatment/prevention of cancer |
| JP6635374B2 (ja) * | 2015-12-18 | 2020-01-22 | 京都府公立大学法人 | 癌におけるリン酸化ｒｂタンパク質を指標としたイリノテカン感受性予測法 |
| US11077110B2 (en) * | 2016-03-18 | 2021-08-03 | Tufts Medical Center | Compositions and methods for treating and preventing metabolic disorders |
| EA202092441A1 (ru) | 2016-06-07 | 2021-05-21 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| MX383803B (es) * | 2016-07-01 | 2025-03-14 | G1 Therapeutics Inc | Sintesis de n-(heteroaril)-pirrolo[3,2-d]pirimidin-2-aminas. |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
| CN109789143A (zh) * | 2016-07-01 | 2019-05-21 | G1治疗公司 | 基于嘧啶的抗增殖剂 |
| MX2019002115A (es) | 2016-08-23 | 2019-07-08 | Eisai R&D Man Co Ltd | Terapias de combinacion para el tratamiento de carcinoma hepatocelular. |
| EP3538148A1 (en) | 2016-11-08 | 2019-09-18 | Dana-Farber Cancer Institute | Compositions and methods of modulating anti-tumor immunity |
| CA3045465A1 (en) | 2016-12-05 | 2018-06-14 | G1 Therapeutics, Inc. | Preservation of immune response during chemotherapy regimens |
| MX2019008158A (es) | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
| US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| CN110325191A (zh) | 2017-02-22 | 2019-10-11 | G1治疗公司 | 以较少的副作用治疗egfr-驱动的癌症 |
| SG11201908531WA (en) | 2017-03-16 | 2019-10-30 | Eisai R&D Man Co Ltd | Combination therapies for the treatment of breast cancer |
| US10988466B2 (en) | 2017-03-23 | 2021-04-27 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic derivatives useful as SHP2 inhibitors |
| KR102659211B1 (ko) | 2017-06-29 | 2024-04-18 | 쥐원 쎄라퓨틱스, 인크. | G1t38의 형체 형태 및 그의 제조 방법 |
| JP7233743B2 (ja) | 2017-08-11 | 2023-03-07 | 晟科薬業（江蘇）有限公司 | プロテインキナーゼ阻害剤としての１ｈ－ピラゾロ［４，３－ｈ］キナゾリン系化合物 |
| JP2021509680A (ja) | 2018-01-08 | 2021-04-01 | ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｇ１ｔ３８の優れた投与レジメン |
| BR112020015431A2 (pt) | 2018-02-15 | 2020-12-08 | Nuvation Bio Inc. | Compostos heterocíclicos como inibidores de quinase |
| AU2019253706A1 (en) * | 2018-04-09 | 2020-11-26 | G1 Therapeutics, Inc. | Treatment of cancers having driving oncogenic mutations |
| CA3107750A1 (en) | 2018-07-27 | 2020-01-30 | California Institute Of Technology | Cdk inhibitors and uses thereof |
| KR20210049847A (ko) | 2018-08-24 | 2021-05-06 | 쥐원 쎄라퓨틱스, 인크. | 1,4-디아자스피로[5.5]운데칸-3-온의 개선된 합성 |
| US20210393623A1 (en) | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
| WO2020097625A1 (en) * | 2018-11-09 | 2020-05-14 | G1 Therapeutics, Inc. | Therapeutic regimens for treatment of cancer using eribulin and selective cdk4/6 inhibitor combinations |
| WO2020206035A1 (en) * | 2019-04-01 | 2020-10-08 | G1 Therapeutics, Inc. | Treatment of cdk4/6 inhibitor resistant neoplastic disorders |
| TW202114684A (zh) * | 2019-06-18 | 2021-04-16 | 美商G1治療公司 | 增強癌症病患之抗腫瘤免疫之方法 |
| TW202128174A (zh) * | 2019-10-09 | 2021-08-01 | 美商G1治療公司 | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 |
| EP4652997A2 (en) * | 2020-05-19 | 2025-11-26 | Pharmacosmos Holding A/s | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| BR112022024484A2 (pt) * | 2020-06-11 | 2022-12-27 | Lunella Biotech Inc | Terapias contra o câncer com o inibidor seletivo de cdk4/6 |
| CN116157403B (zh) * | 2020-06-15 | 2025-04-25 | 海南先声再明医药股份有限公司 | 曲拉西利的形态及其制造方法 |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| CN113788837B (zh) * | 2021-08-02 | 2022-08-26 | 深圳湾实验室坪山生物医药研发转化中心 | Trilaciclib的合成方法 |
| JP2023148228A (ja) * | 2022-03-30 | 2023-10-13 | 東芝ライテック株式会社 | 照明制御装置及び照明制御システム |
| WO2024073507A1 (en) | 2022-09-28 | 2024-04-04 | Theseus Pharmaceuticals, Inc. | Macrocyclic compounds and uses thereof |
| WO2024116069A1 (en) * | 2022-11-28 | 2024-06-06 | Assia Chemical Industries Ltd. | Novel trilaciclib intermediates, method of preparation and use thereof |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5591855A (en) | 1994-10-14 | 1997-01-07 | Cephalon, Inc. | Fused pyrrolocarbazoles |
| US5628984A (en) | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
| EP0964864B1 (en) | 1997-02-05 | 2008-04-09 | Warner-Lambert Company LLC | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US20040006074A1 (en) | 1998-04-28 | 2004-01-08 | The Government Of The United States Of America | Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer |
| EP1086105B1 (en) | 1998-06-16 | 2006-03-01 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Fused azepinone cyclin dependent kinase inhibitors |
| ATE380548T1 (de) | 1999-01-29 | 2007-12-15 | Univ Illinois | Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie |
| AU6314900A (en) | 1999-07-26 | 2001-02-13 | Banyu Pharmaceutical Co., Ltd. | Biarylurea derivatives |
| US6387900B1 (en) | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
| US6291504B1 (en) | 1999-10-20 | 2001-09-18 | Dupont Pharmaceuticals Company | Acylsemicarbazides and their uses |
| US6867198B2 (en) | 1999-12-16 | 2005-03-15 | Eli Lilly And Company | Agents and methods for the treatment of proliferative diseases |
| US7053070B2 (en) | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| DK1686130T3 (da) | 2000-06-26 | 2009-04-06 | Pfizer Prod Inc | Pyrrolo-[2,3-d]-pyrimidinforbindelser som immunsuppressive midler |
| ES2220811T3 (es) | 2000-09-29 | 2004-12-16 | Eli Lilly And Company | Procedimiento y compuestos para el tratamiento de enfermedades proliferativas. |
| AU2002228692A1 (en) | 2000-12-01 | 2002-06-11 | Bristol-Myers Squibb Pharma Company | 3-(2,4-dimethylthiazol-5-yl) indeno(1,2-c)pyrazol-4-one derivatives as cdk inhibitors |
| DE60228692D1 (de) | 2001-02-28 | 2008-10-16 | Univ Temple | Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung |
| KR100863624B1 (ko) | 2001-05-11 | 2008-10-15 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Ｃｄ26을 발현하는 세포와 연관된 질환의 치료제로사용되는 항-ｃｄ26 단클론항체 |
| MEP46108A (en) | 2002-01-22 | 2011-02-10 | Warner Lambert Co | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES |
| CA2495787A1 (en) | 2002-05-01 | 2003-11-13 | Chromos Molecular Systems, Inc. | Methods for delivering nucleic acid molecules into cells and assessment thereof |
| EP1590341B1 (en) | 2003-01-17 | 2009-06-17 | Warner-Lambert Company LLC | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| BRPI0410563B8 (pt) | 2003-05-22 | 2021-05-25 | Nerviano Medical Sciences Srl | compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas |
| PT1648889E (pt) | 2003-07-11 | 2008-12-10 | Warner Lambert Co | Sal isetionato de um inibidor selectivo da cdk4 |
| CA2543308C (en) | 2003-10-23 | 2012-03-06 | F. Hoffman-La Roche Ag | Triaza-spiropiperidine derivatives for use as glyt-1 inhibitors in the treatment of neurological and neuropsychiatric disorders |
| GB0327380D0 (en) | 2003-11-25 | 2003-12-31 | Cyclacel Ltd | Method |
| BRPI0509580A (pt) | 2004-03-30 | 2007-11-27 | Pfizer Prod Inc | combinações de inibidores de transdução de sinal |
| WO2005100999A2 (en) | 2004-04-08 | 2005-10-27 | Cornell Research Foundation, Inc. | Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer |
| ITMI20040874A1 (it) | 2004-04-30 | 2004-07-30 | Ist Naz Stud Cura Dei Tumori | Derivati indolici ed azaindolici con azione antitumorale |
| WO2005117908A2 (en) | 2004-05-28 | 2005-12-15 | Gemin X Biotechnologies, Inc. | Triheterocyclic compounds compositions, and methods for treating cancer or viral diseases |
| ES2411975T3 (es) | 2005-01-14 | 2013-07-09 | Janssen Pharmaceutica Nv | Pirimidinas heterocíclicas anilladas de 5 miembros como inhibidores de cinasas |
| BRPI0606319A2 (pt) | 2005-01-21 | 2009-06-16 | Astex Therapeutics Ltd | compostos farmacêuticos |
| EP2354139A1 (en) | 2005-05-20 | 2011-08-10 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| EP1779848A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
| US7579351B2 (en) | 2005-12-09 | 2009-08-25 | Hoffmann-La Roche Inc. | Tricyclic amide derivatives |
| JP2009524589A (ja) | 2005-12-22 | 2009-07-02 | ワイス | 置換されたイソキノリン−１，３（２ｈ，４ｈ）−ジオン、１−チオキソ−１，４−ジヒドロ−２ｈ−イソキノリン−３−オン誘導体、および１，４−ジヒドロ−３（２ｈ）−イソキノロン、ならびにキナーゼインヒビターとしてのそれらの使用 |
| CN101415409B (zh) | 2006-04-05 | 2012-12-05 | 诺瓦提斯公司 | 用于治疗癌症的治疗剂的组合 |
| US20070270362A1 (en) | 2006-05-18 | 2007-11-22 | The University Of Washington | Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders |
| US8222256B2 (en) | 2006-07-05 | 2012-07-17 | Exelixis, Inc. | Methods of using IGFIR and ABL kinase modulators |
| CA2662587C (en) | 2006-09-11 | 2013-08-06 | Curis, Inc. | Quinazoline based egfr inhibitors |
| JP2010513317A (ja) | 2006-12-14 | 2010-04-30 | パナシー ファーマシューティカルズ インコーポレーティッド | サイクリン依存性キナーゼの阻害による神経保護方法 |
| KR20090091306A (ko) | 2006-12-22 | 2009-08-27 | 노파르티스 아게 | 암, 염증 및 바이러스 감염 치료용 ｃｄｋ 억제제로서의 헤테로아릴-헤테로아릴 화합물 |
| CA2690748A1 (en) | 2007-06-25 | 2008-12-31 | Neurogen Corporation | Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues |
| US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
| WO2009085185A1 (en) | 2007-12-19 | 2009-07-09 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| JP5579715B2 (ja) | 2008-07-29 | 2014-08-27 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ |
| US8685980B2 (en) | 2008-08-22 | 2014-04-01 | Novartis Ag | Pyrrolopyrimidine compounds and their uses |
| CA2738925A1 (en) * | 2008-10-01 | 2010-04-08 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
| WO2010051127A2 (en) | 2008-10-01 | 2010-05-06 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| WO2010132725A2 (en) * | 2009-05-13 | 2010-11-18 | The University Of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| US9040519B2 (en) | 2010-02-18 | 2015-05-26 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| UY33226A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| FR2957748B1 (fr) * | 2010-03-16 | 2012-09-07 | St Microelectronics Grenoble 2 | Composant electronique a montage en surface |
| CN102299073A (zh) | 2010-06-25 | 2011-12-28 | 无锡华润上华半导体有限公司 | Vdmos器件及其制作方法 |
| US8691830B2 (en) * | 2010-10-25 | 2014-04-08 | G1 Therapeutics, Inc. | CDK inhibitors |
| EP2632467B1 (en) * | 2010-10-25 | 2016-06-22 | G1 Therapeutics, Inc. | Cdk inhibitors |
| AU2011323455B2 (en) | 2010-11-02 | 2017-07-27 | Promega Corporation | Coelenterazine derivatives and methods of using same |
| CN103501789A (zh) | 2010-11-17 | 2014-01-08 | 北卡罗来纳大学查珀尔希尔分校 | 通过抑制增殖性激酶cdk4和cdk6保护肾组织免于局部缺血 |
| HUE024504T2 (en) | 2010-12-23 | 2016-01-28 | Sanofi Sa | Pyrimidine derivatives, a process for their preparation and their use in medicine |
| WO2012129344A1 (en) | 2011-03-23 | 2012-09-27 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| BR112013033940A2 (pt) | 2011-07-01 | 2017-02-14 | Novartis Ag | terapia combinada compreendendo um inibidor de cdk4/6 e um inibidor de pi3k para uso no tratamento de câncer |
| JP5427321B2 (ja) | 2011-07-27 | 2014-02-26 | アストラゼネカ アクチボラグ | ２−（２，４，５−置換−アニリノ）ピリミジン化合物 |
| EP3216792B1 (en) | 2012-03-29 | 2020-05-27 | G1 Therapeutics, Inc. | Lactam kinase inhibitors |
| CN104302620A (zh) | 2012-04-26 | 2015-01-21 | 弗朗西斯·泽维尔·塔瓦雷斯 | 内酰胺的合成 |
| EP2880448B1 (en) | 2012-08-03 | 2022-06-29 | Foundation Medicine, Inc. | Human papilloma virus as predictor of cancer prognosis |
| US9241941B2 (en) | 2012-09-20 | 2016-01-26 | Memorial Sloan-Kettering Cancer Center | Methods for treatment of lymphomas with mutations in cell cycle genes |
| RU2015125307A (ru) | 2012-11-28 | 2017-01-10 | Новартис Аг | Комбинированная терапия |
| WO2014144847A2 (en) * | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Hspc-sparing treatments for rb-positive abnormal cellular proliferation |
| CN105407723A (zh) * | 2013-03-15 | 2016-03-16 | G1治疗公司 | 高效的抗赘生剂和抗增生剂 |
| US20140274896A1 (en) | 2013-03-15 | 2014-09-18 | G1 Therapeutics, Inc. | Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
| BR112015025711A8 (pt) | 2013-04-08 | 2019-12-17 | Janssen Pharmaceutica Nv | uso de ibrutinibe e coposição farmacêutica compreendendo ibrutinibe e um agente anticâncer |
| SG10201709926VA (en) | 2013-05-30 | 2017-12-28 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| US20160257688A1 (en) | 2013-10-24 | 2016-09-08 | Francis Xavier Tavares | Process for Synthesis of Lactams |
| US10314842B2 (en) | 2013-12-02 | 2019-06-11 | Cornell University | Methods for treating B cell proliferative disorders |
| PL3091008T3 (pl) | 2013-12-31 | 2018-12-31 | Xuanzhu Pharma Co., Ltd. | Inhibitor kinazy i jego zastosowanie |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| WO2015161285A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation |
| EP3191098A4 (en) * | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| US9374037B2 (en) | 2014-10-30 | 2016-06-21 | M/A-Com Technology Solutions Holdings, Inc. | Voltage-controlled oscillator with mask-selectable performance |
| US20160220569A1 (en) | 2015-02-03 | 2016-08-04 | G1 Therapeutics, Inc. | CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy |
| MX383803B (es) * | 2016-07-01 | 2025-03-14 | G1 Therapeutics Inc | Sintesis de n-(heteroaril)-pirrolo[3,2-d]pirimidin-2-aminas. |
| WO2018005863A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| CA3045465A1 (en) * | 2016-12-05 | 2018-06-14 | G1 Therapeutics, Inc. | Preservation of immune response during chemotherapy regimens |
| CN110267659A (zh) * | 2016-12-08 | 2019-09-20 | 西奈山伊坎医学院 | 用于治疗cdk4/6介导的癌症的组合物和方法 |
| MX2019008158A (es) * | 2017-01-06 | 2019-12-09 | G1 Therapeutics Inc | Terapia de combinacion para el tratamiento del cancer. |
| US11395821B2 (en) * | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
| US10208011B2 (en) * | 2017-02-10 | 2019-02-19 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
| CN110325191A (zh) * | 2017-02-22 | 2019-10-11 | G1治疗公司 | 以较少的副作用治疗egfr-驱动的癌症 |
| KR102659211B1 (ko) * | 2017-06-29 | 2024-04-18 | 쥐원 쎄라퓨틱스, 인크. | G1t38의 형체 형태 및 그의 제조 방법 |
| WO2019136244A1 (en) | 2018-01-04 | 2019-07-11 | G1 Therapeutics, Inc. | Heterocyclic compounds for the treatment of abnormal cellular proliferation |
| JP2021509680A (ja) * | 2018-01-08 | 2021-04-01 | ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｇ１ｔ３８の優れた投与レジメン |
| AU2019253706A1 (en) * | 2018-04-09 | 2020-11-26 | G1 Therapeutics, Inc. | Treatment of cancers having driving oncogenic mutations |
| WO2020023502A1 (en) * | 2018-07-23 | 2020-01-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| TW202114684A (zh) * | 2019-06-18 | 2021-04-16 | 美商G1治療公司 | 增強癌症病患之抗腫瘤免疫之方法 |
| TW202128174A (zh) * | 2019-10-09 | 2021-08-01 | 美商G1治療公司 | 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療 |
-
2014
- 2014-03-14 WO PCT/US2014/029429 patent/WO2014144847A2/en not_active Ceased
- 2014-03-14 EP EP14762438.1A patent/EP2968290B1/en active Active
- 2014-03-14 CN CN201810253672.1A patent/CN108283644B/zh active Active
- 2014-03-14 US US14/214,048 patent/US9527857B2/en active Active
- 2014-03-14 CN CN201480027269.7A patent/CN105407889B/zh active Active
- 2014-03-14 CA CA2906166A patent/CA2906166C/en active Active
- 2014-03-14 ES ES14765105T patent/ES3032492T3/es active Active
- 2014-03-14 JP JP2016503092A patent/JP6337083B2/ja active Active
- 2014-03-14 RS RS20191537A patent/RS59790B1/sr unknown
- 2014-03-14 HR HRP20192168TT patent/HRP20192168T1/hr unknown
- 2014-03-14 DK DK14762438T patent/DK2968290T3/da active
- 2014-03-14 EP EP14765105.3A patent/EP2968291B1/en active Active
- 2014-03-14 EP EP19198057.2A patent/EP3653209A1/en active Pending
- 2014-03-14 JP JP2016502870A patent/JP6430483B2/ja active Active
- 2014-03-14 PT PT147624381T patent/PT2968290T/pt unknown
- 2014-03-14 CN CN201480027281.8A patent/CN105473140B/zh active Active
- 2014-03-14 WO PCT/US2014/028685 patent/WO2014144326A1/en not_active Ceased
- 2014-03-14 EP EP25170501.8A patent/EP4596051A3/en active Pending
- 2014-03-14 SM SM20190681T patent/SMT201900681T1/it unknown
- 2014-03-14 US US14/212,430 patent/US9487530B2/en active Active
- 2014-03-14 PL PL14762438T patent/PL2968290T3/pl unknown
- 2014-03-14 ME MEP-2019-338A patent/ME03557B/me unknown
- 2014-03-14 CN CN201810443050.5A patent/CN108434149B/zh active Active
- 2014-03-14 CA CA2906156A patent/CA2906156C/en active Active
- 2014-03-14 SI SI201431380T patent/SI2968290T1/sl unknown
- 2014-03-14 ES ES14762438T patent/ES2761406T3/es active Active
- 2014-03-14 HU HUE14762438A patent/HUE046653T2/hu unknown
- 2014-03-14 US US14/212,911 patent/US9464092B2/en active Active
- 2014-03-14 LT LT14762438T patent/LT2968290T/lt unknown
-
2016
- 2016-10-07 US US15/288,878 patent/US9931345B2/en active Active
- 2016-11-03 US US15/342,990 patent/US10085992B2/en active Active
- 2016-12-21 US US15/387,083 patent/US10076523B2/en active Active
-
2018
- 2018-04-02 US US15/943,278 patent/US10660896B2/en active Active
- 2018-05-07 JP JP2018089382A patent/JP6517401B2/ja active Active
- 2018-08-24 US US16/112,362 patent/US10434104B2/en active Active
- 2018-08-24 US US16/112,360 patent/US10966984B2/en active Active
- 2018-10-30 JP JP2018204234A patent/JP6767456B2/ja active Active
- 2018-11-01 US US16/178,419 patent/US10925878B2/en active Active
-
2019
- 2019-04-16 JP JP2019077828A patent/JP6738933B6/ja active Active
- 2019-12-11 CY CY20191101306T patent/CY1122434T1/el unknown
-
2020
- 2020-05-28 US US16/886,309 patent/US11040042B2/en active Active
- 2020-07-17 JP JP2020123189A patent/JP7250737B2/ja active Active
- 2020-09-16 JP JP2020155691A patent/JP7213854B2/ja active Active
-
2021
- 2021-02-22 US US17/181,638 patent/US11654148B2/en active Active
- 2021-04-05 US US17/222,873 patent/US11717523B2/en active Active
-
2023
- 2023-01-17 JP JP2023005413A patent/JP2023052449A/ja not_active Ceased
- 2023-03-06 US US18/117,983 patent/US20230364098A1/en active Pending
- 2023-03-20 JP JP2023044746A patent/JP2023078341A/ja not_active Withdrawn
- 2023-08-07 US US18/231,091 patent/US20230381189A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513737A5 (enExample) | ||
| JP6912486B2 (ja) | Ｒｓｋ阻害剤として有用なカルボキサミド誘導体 | |
| JP2017511360A5 (enExample) | ||
| JP2013512903A5 (enExample) | ||
| JP6754071B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2007529421A5 (enExample) | ||
| RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
| TR201802944T4 (tr) | İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇ | |
| RU2017145026A (ru) | Соединение, ингибирующее brk | |
| JP6456383B2 (ja) | イソチオシアネート系化合物と抗癌薬の併用 | |
| HRP20150489T1 (hr) | Imidazo[4,5-c]kinolini kao inhibitori dna-pk | |
| JP2010539098A5 (enExample) | ||
| JP2016506916A5 (enExample) | ||
| MX387207B (es) | Inhibidores de proteína quinasa, método de preparación y su uso médico. | |
| KR101848131B1 (ko) | 저용량 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| RU2018127728A (ru) | Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич | |
| WO2017192991A1 (en) | Selective estrogen receptor down-regulators (serds) | |
| JO3434B1 (ar) | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري | |
| WO2020047487A1 (en) | Methods for treating cancer with rorgamma inhibitors and statins | |
| AU2016250099A1 (en) | Methods of treating hepatitis B virus | |
| EP2906564A1 (en) | Treating brain cancer using agelastatin a (aa) and analogues thereof | |
| RU2011150619A (ru) | Комбинация ингибитора фосфоинозитид-3-киназы и противодиабетического соединения | |
| AU2012336154B2 (en) | Combination therapy for ovarian cancer |